< 1 min read|01/01/2017
Policy Options for Formulary Development in Middle-income Countries
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion.
This report presents a framework for developing medicines formularies which combines macro-level decision making factors (focusing on the…
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion.
This report presents a framework for developing medicines formularies which combines macro-level decision making factors (focusing on the health system organisation and its priority setting), and micro-level factors (looking at intervention-specific effects) to determine the overall value of medicines.
In a susbequent publication (click here) we apply this framework to analyse the Mexican decision making process for the inclusion of a new health treatment in the positive list. We propose a series of recommendations that could improve the efficiency of the Mexican decision making process.
Policy Options for Formulary Development in Middle-income Countries
Hernandez-Villafuerte, K., Garau, M., Towse, A., Garrison, L. and Grewal, S. (2017) Policy Options for Formulary Development in Middle-income Countries.
OHE Contract Research. Available from https://www.ohe.org/publications/policy-options-formulary-development-middle-income-countries/